Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares Jun 24, 2020 4:34pm EDT
Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis Jun 17, 2020 8:47am EDT
Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format Jun 05, 2020 4:15pm EDT
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants May 26, 2020 4:05pm EDT
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress May 26, 2020 7:00am EDT
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress May 19, 2020 8:30am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 18, 2020 4:30pm EDT
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 May 15, 2020 9:38am EDT
